Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain healing

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Brain healing. Displaying page 1 of 1.
    EudraCT Number: 2012-001249-41 Sponsor Protocol Number: KEK-ZH-2012-0249 Start Date*: 2013-04-12
    Sponsor Name:University Hospital of Zurich and City Hospital Waid
    Full Title: Vitamin D3 – Omega3 – Home Exercise – HeALTHy Ageing and Longevity Trial Randomized, double-blind, placebo-controlled, multi-centre clinical trial
    Medical condition: healthy ageing, functional decline
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PT (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016501-41 Sponsor Protocol Number: 400-09-001 Start Date*: 2010-06-29
    Sponsor Name:Omrix Biopharmaceuticals Ltd
    Full Title: A Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Evicel as an Adjunct to Sutured Dural Repair
    Medical condition: tissue adhesion/sealing and suture support in neurosurgery and surgical procedures where contact with cerebrospinal fluid or dura mater can occur e.g. otologic, rhinologic, ophthalmic and vertebral...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004175-73 Sponsor Protocol Number: HP-CD-CL-2002 Start Date*: 2017-09-27
    Sponsor Name:Herantis Pharma Plc
    Full Title: A Phase I-II, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intermittent Bilateral Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Administere...
    Medical condition: Idiopathic Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-001554-33 Sponsor Protocol Number: BGB-290-104 Start Date*: 2018-01-24
    Sponsor Name:BeiGene USA, Inc.
    Full Title: A Phase 1b/2 study to assess the safety, tolerability and efficacy of BGB-290 in combination with radiation therapy and/or temozolomide in subjects with first-line or recurrent/refractory glioblastoma
    Medical condition: glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004944-37 Sponsor Protocol Number: MK-3475-054-07 Start Date*: 2015-09-22
    Sponsor Name:Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc
    Full Title: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial o...
    Medical condition: Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2004-000975-32 Sponsor Protocol Number: RPCE03L1801 Start Date*: 2004-11-09
    Sponsor Name:UCB S.A. - Pharma Sector
    Full Title: An exploratory, double blind, randomized, placebo-controlled, prallel group, multicenter study, for the assessment of the efficacy, safety and tolerability of ucb34714 50mg oral capsules in b.i.d. ...
    Medical condition: post-herpetic neuralgia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-004053-91 Sponsor Protocol Number: CO19/121741 Start Date*: 2020-07-06
    Sponsor Name:University of Leeds
    Full Title: Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma
    Medical condition: Recurrent Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-003896-35 Sponsor Protocol Number: EORTC 26041_22041 Start Date*: 2005-08-01
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase I/II study on concomitant and adjuvant Temozolomide and Radiotherapy with or without PTK787/ZK222584 in newly diagnosed GBM
    Medical condition: Glioblastoma multiforme
    Disease: Version SOC Term Classification Code Term Level
    7.1 10018337 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) AT (Completed) GB (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-001155-11 Sponsor Protocol Number: OSI-904-202 Start Date*: 2005-02-25
    Sponsor Name:OSI Pharmaceuticals, Inc.
    Full Title: A Randomized, Open Label, Phase II Study of OSI-7904L versus 5-FU/LV as First-Line Treatment in Patients with Unresectable, Locally Advanced or Metastatic Adenocarcinoma of the Biliary Tract
    Medical condition: Unresectable, locally advanced or metastatic adenocarcinoma of the biliary tract
    Disease: Version SOC Term Classification Code Term Level
    10004594
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006342-32 Sponsor Protocol Number: 75111-10114 Start Date*: 2013-06-11
    Sponsor Name:EORTC
    Full Title: Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression whi...
    Medical condition: Newly diagnosed or recurrent (after surgery) stage IV (TNM/AJCC v.7) HER-2 positive (IHC 3+ or or HER-2 gene amplification by in situ hybridization) invasive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) PT (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000874-67 Sponsor Protocol Number: NO25390 Start Date*: 2011-11-04
    Sponsor Name:F. Hoffman-La Roche Ltd.
    Full Title: An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of vemurafenib (RO5185426) in pediatric patients with surgically incurable and unresectable Stage ...
    Medical condition: Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Completed) IT (Prematurely Ended) SK (Prematurely Ended) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003024-33 Sponsor Protocol Number: D5162C00048 Start Date*: 2023-01-13
    Sponsor Name:AstraZeneca AB
    Full Title: An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation-Posi...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012857-39 Sponsor Protocol Number: A4021032 Start Date*: 2009-11-16
    Sponsor Name:PFIZER, S.A.
    Full Title: “ESTUDIO DE FASE 2, ALEATORIZADO Y ABIERTO DE FIGITUMUMAB (CP-751,871) MÁS CISPLATINO (O CARBOPLATINO) Y ETOPOSIDO, FRENTE A CISPLATINO (O CARBOPLATINO) Y ETOPOSIDO SOLOS, COMO TRATAMIENTO DE PRIME...
    Medical condition: Pacientes con cáncer de pulmón microcítico en estadio extendido que no hayan recibido quimioterapia previa para su enfermedad.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10041068 Small cell lung cancer extensive stage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) BG (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003866-34 Sponsor Protocol Number: 2553 Start Date*: 2012-09-24
    Sponsor Name:North Bristol NHS Trust (NBT)
    Full Title: A Placebo-Controlled, Randomised, Double-Blind Trial to Assess the Safety and Efficacy of Intermittent Bilateral Intraputamenal Glial Cell Line-Derived Neurotrophic Factor (GDNF) Infusions Administ...
    Medical condition: Parkinson's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10034008 Parkinson's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 21:21:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA